{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:22:30Z","timestamp":1790673750921,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.ophtha.2010.12.016","type":"journal-article","created":{"date-parts":[[2011,4,3]],"date-time":"2011-04-03T11:53:00Z","timestamp":1301831580000},"page":"1242-1252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Treatment of Sj\u00f6gren's Syndrome\u2013Associated Dry Eye"],"prefix":"10.1016","volume":"118","author":[{"given":"Esen Karamursel","family":"Akpek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina B.","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit S.","family":"Adyanthaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Swamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan N.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2010.12.016_bib1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00006324-199708000-00023","article-title":"A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada","volume":"74","author":"Doughty","year":"1997","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.ophtha.2010.12.016_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/978-1-4615-0717-8_140","article-title":"Epidemiology of dry eye syndrome","volume":"506","author":"Schaumberg","year":"2002","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","article-title":"Prevalence of dry eye syndrome among US women","volume":"136","author":"Schaumberg","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definitionclassification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ophtha.2010.12.016_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/ICO.0b013e31818d3846","article-title":"Evaluation of patients with dry eye for presence of underlying Sj\u00f6gren syndrome","volume":"28","author":"Akpek","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2010.12.016_bib6","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.ico.0000214802.40313.fa","article-title":"Dysfunctional Tear Syndrome Study Group","volume":"25","author":"Behrens","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2010.12.016_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/bjo.86.8.879","article-title":"Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sj\u00f6gren's syndrome patients","volume":"86","author":"Aragona","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.eye.6700169","article-title":"A randomised, crossover, multicentre study to compare the performance of 0.1% (w\/v) sodium hyaluronate with 1.4% (w\/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome","volume":"16","author":"McDonald","year":"2002","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2010.12.016_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/15027732.1986.12461425","article-title":"Treatment of keratoconjunctivitis sicca with Lacrisert","volume":"61","author":"Prause","year":"1986","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.ophtha.2010.12.016_bib10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/978-1-4615-2417-5_116","article-title":"Effects of sodium sucrose-sulfate on the ocular surface of patients with keratoconjunctivitis sicca in Sj\u00f6gren's syndrome","volume":"350","author":"Prause","year":"1994","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.exer.2003.08.005","article-title":"Flow cytometry in conjunctival impression cytology: a new tool for exploring ocular surface pathologies","volume":"78","author":"Brignole-Baudouin","year":"2004","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2010.12.016_bib12","first-page":"3493","article-title":"Sj\u00f6gren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium","volume":"35","author":"Jones","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2010.12.016_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0161-6420(97)30330-3","article-title":"Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation","volume":"104","author":"Pflugfelder","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.12.016_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/jop.2006.0091","article-title":"Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sj\u00f6gren's syndrome","volume":"23","author":"Hong","year":"2007","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2010.12.016_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","article-title":"Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sj\u00f6gren's syndrome","volume":"72","author":"G\u00fcnd\u00fcz","year":"1994","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.ophtha.2010.12.016_bib16","first-page":"85","article-title":"Topical cyclosporine therapy for keratoconjunctivitis sicca in Sj\u00f6gren's syndrome","volume":"15","author":"Fan","year":"2003","journal-title":"Tzu Chi Med J"},{"key":"10.1016\/j.ophtha.2010.12.016_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF02697322","article-title":"Effect of topical cyclosporine on tear functions in tear-deficient dry eyes","volume":"39","author":"Jain","year":"2007","journal-title":"Ann Ophthalmol (Skokie)"},{"key":"10.1016\/j.ophtha.2010.12.016_bib18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00003226-200003000-00005","article-title":"Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis","volume":"19","author":"Avisar","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2010.12.016_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.eye.6701537","article-title":"Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sj\u00f6gren's syndrome patients","volume":"19","author":"Aragona","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2010.12.016_bib21","first-page":"123","article-title":"Cyclosporine and the immune response: basic aspects","volume":"6","author":"Hess","year":"1986","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/bjo.2003.026211","article-title":"Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease","volume":"88","author":"Noble","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/art.1780270415","article-title":"Beneficial effects of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca","volume":"27","author":"Fox","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ajo.2007.03.016","article-title":"Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome","volume":"144","author":"Yoon","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"P92-01 Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ophtha.2010.12.016_bib26","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","article-title":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sj\u00f6gren's syndrome: a randomised 12 week controlled study","volume":"62","author":"Tsifetaki","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2010.12.016_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.rhu.0000135553.08057.21","article-title":"Successful treatment of dry mouth and dry eye symptoms in Sj\u00f6gren's syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study","volume":"10","author":"Papas","year":"2004","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","article-title":"A double-blind, randomized, placebo-controlled study of cevimeline in Sj\u00f6gren's syndrome patients with xerostomia and keratoconjunctivitis sicca","volume":"46","author":"Petrone","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib29","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","article-title":"Cevimeline for the treatment of xerostomia in patients with Sj\u00f6gren syndrome: a randomized trial","volume":"162","author":"Fife","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ophtha.2010.12.016_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","article-title":"Therapeutic effect of cevimeline on dry eye in patients with Sj\u00f6gren's syndrome: a randomized, double-blind clinical study","volume":"138","author":"Ono","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10067-007-0723-x","article-title":"The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sj\u00f6gren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study","volume":"27","author":"Leung","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1385\/CRIAI:25:1:89","article-title":"Immunopathogenesis of Sj\u00f6gren's syndrome","volume":"25","author":"Borchers","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib33","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.V90.2.766","article-title":"Lymphomas in patients with Sj\u00f6gren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses","volume":"90","author":"Royer","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ophtha.2010.12.016_bib34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"suppl","key":"10.1016\/j.ophtha.2010.12.016_bib35","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1177\/0961203393002001031","article-title":"Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation","volume":"2","author":"Fox","year":"1993","journal-title":"Lupus"},{"key":"10.1016\/j.ophtha.2010.12.016_bib36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"issue":"suppl","key":"10.1016\/j.ophtha.2010.12.016_bib37","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/0961203396005001081","article-title":"Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine: a retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.ophtha.2010.12.016_bib38","first-page":"292","article-title":"Ocular safety of hydroxychloroquine","volume":"23","author":"Bernstein","year":"1991","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib39","doi-asserted-by":"crossref","unstructured":"Yavuz S, Asfuro\u011flu E, Bicakcigil M, Toker E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sj\u00f6gren's syndrome. Rheumatol Int 2010 Mar 23 [Epub ahead of print].","DOI":"10.1007\/s00296-010-1415-4"},{"key":"10.1016\/j.ophtha.2010.12.016_bib40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ophtha.2010.12.016_bib41","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Club Rhumatismes et Inflammation (CRI)","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2010.12.016_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2010.12.016_bib43","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2010.12.016_bib44","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib45","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren's syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib47","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sj\u00f6gren's syndrome: a pilot study","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib48","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1002\/art.10674","article-title":"Infliximab in primary Sj\u00f6gren's syndrome: one-year followup","volume":"46","author":"Steinfeld","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib49","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of in primary Sj\u00f6gren syndrome: results of the randomized, controlled trial of Remicade in primary Sj\u00f6gren syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib50","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib51","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sj\u00f6gren's syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib52","first-page":"402","article-title":"Treatment of primary Sj\u00f6gren's syndrome with D-penicillamine: a pilot study","volume":"60","author":"ter Borg","year":"2002","journal-title":"Neth J Med"},{"key":"10.1016\/j.ophtha.2010.12.016_bib53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.ophtha.2010.12.016_bib54","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar2322","article-title":"Mycophenolate sodium treatment in patients with primary Sj\u00f6gren syndrome: a pilot trial","volume":"9","author":"Willeke","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ophtha.2010.12.016_bib55","first-page":"367","article-title":"Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sj\u00f6gren's syndrome patients: preliminary results of an open pilot trial versus OH-chloroquine","volume":"14","author":"Ferraccioli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib56","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.45.9.732","article-title":"Cyclosporin (CyA) in primary Sj\u00f6gren's syndrome: a double blind study","volume":"45","author":"Drosos","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2010.12.016_bib57","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15027732.1986.12461421","article-title":"Cyclosporin A therapy in patients with primary Sj\u00f6grens' syndrome: results at one year","volume":"61","author":"Drosos","year":"1986","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.ophtha.2010.12.016_bib58","unstructured":"Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sj\u00f6gren's syndrome. Clin Exp Rheumatol 93;11:149\u201356."},{"key":"10.1016\/j.ophtha.2010.12.016_bib59","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bmj.1.6127.1579","article-title":"Sj\u00f6gren's syndrome treated with bromhexine: a randomised clinical study","volume":"1","author":"Frost-Larsen","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.ophtha.2010.12.016_bib60","first-page":"971","article-title":"Clinical trial of bromhexidine in Sj\u00f6gren's syndrome","volume":"13","author":"Avisar","year":"1981","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib61","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/bmj.280.6228.1356","article-title":"Sj\u00f6gren's syndrome treated with bromhexine: a reassessment","volume":"280","author":"Tapper-Jones","year":"1980","journal-title":"Br Med J"},{"key":"10.1016\/j.ophtha.2010.12.016_bib62","first-page":"403","article-title":"Effect of prolonged bromhexine therapy on Sj\u00f6gren's syndrome","volume":"17","author":"Nahir","year":"1981","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.ophtha.2010.12.016_bib63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1272\/jnms1923.55.191","article-title":"Effect of bromhexine on Sj\u00f6gren's syndrome accompanied by rheumatoid arthritis","volume":"55","author":"Kawashima","year":"1988","journal-title":"Nippon Ika Daigaku Zasshi"},{"key":"10.1016\/j.ophtha.2010.12.016_bib64","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1755-3768.1981.tb03008.x","article-title":"Lack of lacrimal gland improvement by NA-872 in Sj\u00f6gren's syndrome","volume":"59","author":"Manthorpe","year":"1981","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.ophtha.2010.12.016_bib65","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/03009748109095294","article-title":"Bromhexine treatment of Sj\u00f6gren's syndrome: effect on lacrimal and salivary secretion, and on proteins in tear fluid and saliva","volume":"10","author":"Manthorpe","year":"1981","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1755-3768.1984.tb08430.x","article-title":"Lacrimal and salivary secretion in Sj\u00f6gren's syndrome: the effect of systemic treatment with bromhexine","volume":"62","author":"Prause","year":"1984","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.ophtha.2010.12.016_bib67","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1755-3768.1984.tb03965.x","article-title":"Mucosolvan in the treatment of patients with primary Sj\u00f6gren's syndrome: results from a double-blind cross-over investigation","volume":"62","author":"Manthorpe","year":"1984","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.ophtha.2010.12.016_bib68","first-page":"165","article-title":"Clinical trial of ambroxol (Mucosolvan) in Sj\u00f6gren's syndrome","volume":"13","author":"Ichikawa","year":"1988","journal-title":"Tokai J Exp Clin Med"},{"key":"10.1016\/j.ophtha.2010.12.016_bib69","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1210\/jc.2009-0106","article-title":"Low serum levels of sex steroids are associated with disease characteristics in primary Sj\u00f6gren's syndrome: supplementation with dehydroepiandrosterone restores the concentrations","volume":"94","author":"Forsblad-d'Elia","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2010.12.016_bib70","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20540","article-title":"Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sj\u00f6gren's syndrome","volume":"51","author":"Pillemer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-5751-6-11","article-title":"Effectiveness of low-dose doxycycline (LDD) on clinical symptoms of Sj\u00f6gren's syndrome: a randomized, double-blind, placebo controlled cross-over study","volume":"31","author":"Seitsalo","year":"2007","journal-title":"J Negat Results Biomed"},{"key":"10.1016\/j.ophtha.2010.12.016_bib72","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/ard.2004.031393","article-title":"Lamivudine is not effective in primary Sj\u00f6gren's syndrome","volume":"64","author":"Gescuk","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2010.12.016_bib73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/15027732.1986.12461423","article-title":"A double-blind, cross-over, study of oral N-acetylcysteine in Sj\u00f6gren's syndrome","volume":"61","author":"Walters","year":"1986","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.ophtha.2010.12.016_bib74","first-page":"555","article-title":"Methotrexate in primary Sj\u00f6gren's syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib75","first-page":"53","article-title":"Nandrolone decanoate (deca-durabolin) in primary Sj\u00f6gren's syndrome: a double blind pilot study","volume":"6","author":"Drosos","year":"1988","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib76","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/art.20416","article-title":"Prominent adverse effects of thalidomide in primary Sj\u00f6gren's syndrome [letter]","volume":"51","author":"Pillemer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ophtha.2010.12.016_bib77","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ophtha.2007.06.027","article-title":"Lactoferrin in Sj\u00f6gren's syndrome [letter]","volume":"114","author":"Dogru","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2010.12.016_bib78","doi-asserted-by":"crossref","unstructured":"Egrilmez S, Aslan F, Karabulut G, et al. Clinical efficacy of the Smartplug in the treatment of primary Sj\u00f6gren's syndrome with keratoconjunctivitis sicca: one-year follow-up study. Rheumatol Int 2010 May 21 [Epub ahead of print].","DOI":"10.1007\/s00296-010-1527-x"},{"key":"10.1016\/j.ophtha.2010.12.016_bib79","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.ico.0000244877.30997.6a","article-title":"Lacrimal punctum occlusion in the treatment of severe keratoconjunctivitis sicca caused by Sj\u00f6gren syndrome: a uniocular evaluation","volume":"26","author":"Mansour","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.ophtha.2010.12.016_bib80","first-page":"115","article-title":"Polyunsaturated fatty acids and rheumatoid arthritis","volume":"4","author":"Calder","year":"2001","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.ophtha.2010.12.016_bib81","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1167\/iovs.04-1394","article-title":"Systemic omega-6 essential fatty acid treatment and PGE1 tear content in Sj\u00f6gren's syndrome patients","volume":"46","author":"Aragona","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2010.12.016_bib82","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00541208","article-title":"Primary Sj\u00f6gren's syndrome treated with efamil\/efavit: a double-blind cross-over investigation","volume":"4","author":"Manthorpe","year":"1984","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ophtha.2010.12.016_bib83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/03009748609102073","article-title":"Patients with primary Sj\u00f6gren's syndrome treated for two months with evening primrose oil","volume":"15","author":"Oxholm","year":"1986","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ophtha.2010.12.016_bib84","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/03009740252937577","article-title":"Gammalinolenic acid treatment of fatigue associated with primary Sj\u00f6gren's syndrome","volume":"31","author":"Theander","year":"2002","journal-title":"Scand J Rheumatol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642010013308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642010013308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:00:41Z","timestamp":1758981641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642010013308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0161642010013308"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2010.12.016","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Sj\u00f6gren's Syndrome\u2013Associated Dry Eye","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2010.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}